CGS-20625
Chemical compound
- none
- 5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one
- 111205-55-1
Y
- 163844
- 143700
N
- K9Q4R9S81O
- DTXSID30912046
- Interactive image
- COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2
InChI
- InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,20H,2-6H2,1H3N
- Key:UBLXQFIFWUEVGJ-UHFFFAOYSA-NN
N
Y (what is this?) (verify)CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs,[1] but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.[2][3] It produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects.[4] It is orally active in humans, but with relatively low bioavailability.[5]
CGS-20625 is a positive allosteric modulator at several GABAA receptors types. Due to its alicyclic moiety potency at γ1 subunit, containing receptor types is more pronounced for CGS-20625 compared to benzodiazepines.[1] γ1 subunits are expressed at higher levels in the central amygdala.[6]
References
- ^ a b Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S (Feb 2006). "Pharmacological properties of GABAA receptors containing gamma1 subunits". Mol. Pharmacol. 69 (2): 640–9. doi:10.1124/mol.105.017236. PMID 16272224. S2CID 15082432.
- ^ Bennett DA (1987). "Pharmacology of the pyrazolo-type compounds: agonist, antagonist and inverse agonist actions". Physiol. Behav. 41 (3): 241–5. doi:10.1016/0031-9384(87)90360-X. PMID 2893398. S2CID 45892825.
- ^ Brunner LA, Luders RC (Aug 1991). "Determination of a potential anxiolytic drug (CGS 20625) in human plasma by high-performance liquid chromatography". J. Chromatogr. 568 (2): 487–93. doi:10.1016/0378-4347(91)80188-I. PMID 1686029.
- ^ Williams M, Bennett DA, Loo PS, et al. (Jan 1989). "CGS 20625, a novel pyrazolopyridine anxiolytic". J Pharmacol Exp Ther. 248 (1): 89–96. PMID 2563294.
- ^ Hirschberg Y, Oberle RL, Ortiz M, Lau H, Markowska M (Feb 1995). "Oral absorption of CGS-20625, an insoluble drug, in dogs and man". J Pharmacokinet Biopharm. 23 (1): 11–23. doi:10.1007/BF02353783. PMID 8576841. S2CID 22126140.
- ^ Esmaeili A, Lynch JW, Sah P (January 2009). "GABAA receptors containing gamma1 subunits contribute to inhibitory transmission in the central amygdala". J. Neurophysiol. 101 (1): 341–9. doi:10.1152/jn.90991.2008. PMID 19004994. S2CID 1590604.
- v
- t
- e
- Benzodiazepines: Adinazolam
- Alprazolam
- Bromazepam
- Camazepam
- Chlordiazepoxide
- Clobazam
- Clonazepam
- Clorazepate
- Clotiazepam
- Cloxazolam
- Diazepam#
- Ethyl loflazepate
- Etizolam
- Fludiazepam
- Halazepam
- Ketazolam
- Lorazepam#
- Medazepam
- Nordazepam
- Oxazepam
- Pinazepam
- Prazepam; Others: Alpidem‡
- Barbiturates (e.g., phenobarbital)
- Carbamates (e.g., meprobamate)
- Carisoprodol
- Chlormezanone‡
- Ethanol (alcohol)
- Etifoxine
(α2δ VDCC blockers)
- SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram)
- SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine)
- SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone)
- TCAsTooltip Tricyclic antidepressants (e.g., clomipramine#)
- TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine)
- MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine
- Bupropion
- Tianeptine
- Vilazodone
- Vortioxetine
(Antiadrenergics)
- Alpha-1 blockers (e.g., prazosin)
- Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine)
- Beta blockers (e.g., propranolol)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
